AstraZeneca Seeks U.S. Emergency Approval for Covid Antibody
- U.K. drugmaker aims to sell drug cocktail to prevent infection
- Antibody could add to growing options beyond just vaccines
This article is for subscribers only.
AstraZeneca Plc submitted its antibody cocktail for U.S. emergency approval to prevent Covid-19 infection as therapeutic options for the pandemic broaden beyond vaccination.
It’s the first regulatory filing for the medicine, which was 77% effective in preventing symptomatic Covid in a clinical trial that included patients with high-risk factors for severe infection.